Estimating the effect of treatment on quality of life in the presence of missing data due to drop-out and death

Quality of Life Research

Volumn 7, Issue 6, 1998, Pages 487-494

  Raboud, J M ^a,b   Singer, J ^a,b   Thorne, A ^b   Schechter, M T ^a,b,c   Shafran, S D ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Canadian HIV Trials Network   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

MAC bactaeremia; Missing data; Non random drop out; Quality of life

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; RIFABUTIN; RIFAMPICIN;

ARTICLE; DATA ANALYSIS; DIAGNOSTIC ERROR; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTEREMIA; CANADA; CLINICAL TRIALS; HUMANS; LOGISTIC MODELS; MYCOBACTERIUM AVIUM COMPLEX; PATIENT DROPOUTS; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC;

EID: 0031691551     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008870223350     Document Type: Article

References (22)

1. Shafran S, Singer J, Zarowny DP, et al. Rifabutin, ethambutol and clarithromycin versus rifampin, ethambutol, clofazimine and ciprofloxacin for mycobacterium avium complex bacteraemia in AIDS patients: a prospective, randomized, multicenter, comparative trial (CTN 010). N Engl J Med 1996; 335: 377-383.
2. Bozzette SA, Kanouse DE, Berry S, Duan N. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. J Am Med Assoc 1995; 273: 295-301.
3. Gelber RD, Lenderking WR, Cotton DJ, et al. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 1992; 116: 961-966.
4. Bozzette SA, Kanouse DE, Duan N, Berry S, Richman DD. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. Antiviral Ther 1996; 1: 21-32.
5. Wu AW, Mathews WC, Brysk LT, et al. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-relatedcomplex. J AIDS 1990; 3: 683-690.
6. Wu AW, Rubin HR, Mathews et al. Functional status and well being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J AIDS 1993; 6: 452-458.
7. Heyting A, Tolboom JTBM, Essers JGA. Statistical handling of drop-outs in longitudinal clinical trials. Stat Med 1992; 11: 2043-2061.
8. Finkelstein DM, Schoenfeld DA. AIDS Clinical Trials, Guidelines for Design and Analysis. New York: John Wiley & Sons, (1995).
9. Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat 1995; 49: 161-169.
10. Bozzette SA, Duan N, Berry S, Kanouse DE. Analytic difficulties in applying quality of life outcomes to clinical trials of therapy for HIV disease. Psychol Health 1994; 9: 143-156.
11. Schumacher M, Olschewski M, Schulgen G. Assessment of quality of life in clinical trials. Stat Med 1991; 10: 1915-1930.
12. Zwinderman AH. Statistical analysis of longitudinal quality of life data with missing measurements. Qual Life Res 1992; 1: 219-224.
13. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic mycobacterium avium complex (MAC) disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905-911.
14. Wu AW, Lichter SL, Richardson W et al. Quality of life in patients receiving clarithromycin for mycobacterium avium complex infection and AIDS. Eighth International Conference on AIDS/III STD World Congress. 1992.
15. Lipsitz SR, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat Med 1994; 13: 1149-1163.
16. Greenlees JS, Reece WS, Zieschang KD. Imputation of missing values when the probability of response depends on the variable being imputed. JASA 1982; 77: 251-261.
17. Safrin S, Finkelstein DM, Feinberg J et al. Comparison of three regimens for treatment of mild to moderate pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. Ann Intern Med 1996; 124: 792-802.
18. The SOCA Research Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996; 114: 23-33.
19. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
20. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decision Making 1989; 9: 142-149.
21. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics 1989; 45: 781-795.
22. Raboud JM, Montaner JSG, Thorne A, Singer J, Schlechter MT. The impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV infected individuals. J AIDS 1996; 12: 46-55.